---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-26-000033"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:04:32.689519+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q1 net loss $44.2M; Jazz's zanidatamab sBLA accepted with Priority Review, PDUFA Aug 25, 2026

## Summary
- Jazz sBLA for zanidatamab in 1L HER2+ GEA accepted with Priority Review; PDUFA target date Aug 25, 2026.
- Upon US FDA approval, Zymeworks eligible for $250M milestone from Jazz; $15M from BeOne for China approval.
- Q1 2026 revenue $2.4M (down 91% YoY from $27.1M); net loss $44.2M vs $22.6M loss in Q1 2025.
- Cash and marketable securities $403.8M as of Mar 31, 2026; $95.8M used for share repurchases under $125M program.
- ZW191 Phase 1 data at AACR: 56% ORR in PROC, 61% in ovarian, 57% in endometrial; FDA Fast Track granted.

## SEC filing metadata
- accession: 0001937653-26-000033
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/0001937653-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/zyme-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-26-000033
- JSON: https://secwatch.observer/filing/0001937653-26-000033.json
- Plain text: https://secwatch.observer/filing/0001937653-26-000033.txt

## Source-grounded claims
- claim_id: bd7c497a2cb8fad97f513346c5ebc64def169887
  claim: Zymeworks Inc. reported financial results for the first quarter March 31, 2026 (three months ended March 31, 2026).
  evidence_excerpt: On May 7, 2026, Zymeworks Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/0001937653-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.